Are patients with hypermobile Ehlers–Danlos syndrome or hypermobility spectrum disorder so different?
Rheumatology International · 2021-10 · 41 (10) · 1785-1794
DOI: 10.1007/s00296-021-04968-3 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Rheumatology International, online erschienen am 16.08.2021. Verfasst von Bérengère Aubry-Rozier und 7 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology, Clinique Bois-Cerf, Lausanne, Switzerland. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Université de Lausanne.
Abstract (Originalsprache)
Diagnosing hypermobile Ehlers–Danlos syndrome (hEDS) remains challenging, despite new 2017 criteria. Patients not fulfilling these criteria are considered to have hypermobile spectrum disorder (HSD). Our first aim was to evaluate whether patients hEDS were more severely affected and had higher prevalence of extra-articular manifestations than HSD. Second aim was to compare their outcome after coordinated physical therapy. Patients fulfilling hEDS/HSD criteria were included in this real-life prospective cohort (November 2017/April 2019). They completed a 16-item Clinical Severity Score (CSS-16). We recorded bone involvement, neuropathic pain (DN4) and symptoms of mast cell disorders (MCAS) as extra-articular manifestations. After a standardized initial evaluation (T0), all patients were offered the same coordinated physical therapy, were followed-up at 6 months (T1) and at least 1 year later (T2), and were asked whether or not their condition had subjectively improved at T2. We included 97 patients (61 hEDS, 36 HSD). Median age was 40 (range 18–73); 92.7% were females. Three items from CSS-16 (pain, motricity problems, and bleeding) were significantly more severe with hEDS than HSD. Bone fragility, neuropathic pain and MCAS were equally prevalent. At T2 (20 months [range 18–26]) 54% of patients reported improvement (no difference between groups). On multivariable analysis, only family history of hypermobility predicted (favorable) outcome ( p = 0.01). hEDS and HDS patients showed similar disease severity score except for pain, motricity problems and bleeding, and similar spectrum of extra-articular manifestations. Long-term improvement was observed in > 50% of patients in both groups. These results add weight to a clinical pragmatic proposition to consider hEDS/HSD as a single entity that requires the same treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Rheumatology, Clinique Bois-Cerf, Lausanne, Switzerland.
- Rehabilitation and Sports Medicine, Providence Hospital, Neuchâtel, Switzerland.
- Rheumatology, HFR Fribourg, Villars-sur-Glâne, Switzerland.
- Physiotherapy, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
- Center for Integrative and Complementary Medicine & Pain Center, Division of Anesthesiology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
- Rheumatology and Rehabilitation, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Förderung
- Université de Lausanne
Zitieren
APA
Aubry-Rozier, B., Schwitzguebel, A., Valerio, F., Tanniger, J., Paquier, C., Berna, C., Hügle, T., & Benaim, C. (2021). Are patients with hypermobile Ehlers–Danlos syndrome or hypermobility spectrum disorder so different?. Rheumatology International, 41(10), 1785-1794. https://doi.org/10.1007/s00296-021-04968-3
Vancouver
Aubry-Rozier B, Schwitzguebel A, Valerio F, Tanniger J, Paquier C, Berna C, et al. Are patients with hypermobile Ehlers–Danlos syndrome or hypermobility spectrum disorder so different?. Rheumatology International. 2021;41(10):1785-1794. doi:10.1007/s00296-021-04968-3
BibTeX
@article{AubryRozier2021,
author = {Aubry-Rozier, Bérengère and Schwitzguebel, Adrien and Valerio, Flore and Tanniger, Joelle and Paquier, Célia and Berna, Chantal and Hügle, Thomas and Benaim, Charles},
title = {Are patients with hypermobile Ehlers–Danlos syndrome or hypermobility spectrum disorder so different?},
journal = {Rheumatology International},
year = {2021},
volume = {41},
number = {10},
pages = {1785--1794},
doi = {10.1007/s00296-021-04968-3}
}
EUVIMED